Abstract:Abstract Background While persistence of chronic symptoms following dengue infection has been documented in small prospective cohorts, population-based studies are limited. The post-acute risk of new-incident multi-systemic complications following dengue infection was contrasted against that following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a multi-ethnic adult Asian population. Methods National testing and healthcare claims that databases in Singapore were utilized to build a retrospective population-based adult cohort with laboratory-confirmed infection during overlapping waves of SARS-CoV-2 and dengue transmission (1 July 2021 to 31 October 2022). Risks of new-incident cardiovascular/neuropsychiatric/autoimmune complications 31–300 days of post-dengue infection, contrasted with SARS-CoV-2 infection, were estimated using Cox regression with overlap weights. Risks were reported in terms of adjusted hazard ratio (aHR) and excess burden per 1000 persons. Results 11 707 dengue-infected individuals and 1 248 326 contemporaneous coronavirus disease 2019 (COVID-19) cases were included; the majority had mild initial infection not requiring hospitalization. Amongst dengue-infected individuals, there was 21% [aHR = 1.21 (1.06–1.38)] increased risk of any sequelae, with 55% [aHR = 1.55 (1.27–1.89)] increased risk of cardiovascular sequelae. Specifically, increased risk of dysrhythmias [aHR = 1.79(1.35–2.37)], ischemic heart disease [aHR = 1.45(1.12–1.89)], other cardiac disorders [aHR = 2.21(1.54–3.16)] and thrombotic disorders [aHR = 2.55(1.50–4.35)] was noted. Elevated risk of individual neuropsychiatric sequelae, including cerebrovascular disorders [aHR = 1.49(1.09–2.13)], cognition/memory disorders [aHR = 2.13(1.55–2.93)], extrapyramidal/movement disorders [aHR = 1.98(1.33–2.94)] and anxiety disorders [aHR = 1.61(1.01–2.56)], was observed in dengue-infected individuals compared to COVID-19 cases. Elevated risks of post-acute sequelae in dengue survivors were observed when contrasted against COVID-19 survivors infected during Delta/Omicron predominance, as well as across vaccination strata. Conclusion Increased risk of post-acute cardiovascular/neuropsychiatric complications was observed in dengue survivors, when contrasted against COVID-19 survivors infected during Delta/Omicron predominance. Research in context Evidence before this study Post-acute sequelae following SARS-CoV-2 infection has been extensively reported; however, long-term sequelae may also occur after other acute infections, such as dengue. While chronic symptom persistence has been reported in small cohorts of dengue survivors, population-based cohort studies are lacking, given dengue’s disproportionate burden in tropical low-and-middle-income countries (LMICs) where access to diagnostic testing and follow-up is limited. We searched PubMed for studies published until 1 March 2024, using search terms ‘dengue’, ‘chronic’, ‘long term’, “with search terms found in abstract, title or MESH headings. Current research on post-acute sequelae following dengue is limited to small prospectively recruited cohorts, impairing generalizability to the population at-large. We only found four population-based retrospective cohort studies from a single country, Taiwan, which examined long-term risk of a limited set of autoimmune and cognitive sequelae following dengue infection. Evidence for post-acute sequelae was mixed, particularly when milder non-hospitalized cases were included. There are no reports on the risk of post-acute sequelae across multiple organ systems following dengue infection, and no reports contrasting the risk of post-acute sequelae in dengue versus SARS-CoV-2 infection. Added value of this study National testing and healthcare claims that databases in Singapore were utilized to build a retrospective population-based adult cohort of laboratory-confirmed dengue and SARS-CoV-2 infections during overlapping waves of COVID-19/dengue transmission. Increased overall risk of any post-acute sequelae and individual cardiovascular/neurological sequelae in dengue-infected adults was observed up to 300 days postinfection, compared against COVID-19 cases infected during Delta/Omicron predominance. While other studies have compared the risk of post-acute sequelae across different respiratory viral infections, such as influenza and SARS-CoV-2, to the best of our knowledge no prior studies have contrasted the potential risks of post-acute sequelae following dengue with that arising after SARS-CoV-2 infection. Implication of all the available evidence Risk of chronic multi-systemic sequelae arising post-dengue infection was significantly elevated when contrasted against post-acute sequelae following COVID-19. Post-acute sequelae may increase the burden of disease attributable to dengue in tropical countries where seasonal outbreaks occur; this is increasingly relevant, given that climate change has broadened the list of countries at risk of dengue endemicity.

Comparative monocyte and T cell responses in DENV-exposed subjects from South-East Asia and DENV-naïve residents in Taiwan

Longitudinal Analysis of Dengue Virus-Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection

Dendritic cell responses to Plasmodium falciparum in a malaria-endemic setting

Frequency of Dengue Virus-Specific T Cells is related to Infection Outcome in Endemic Settings

Increased adaptive immune responses and proper feedback regulation protect against clinical dengue

Association of dengue virus‐specific polyfunctional T‐cell responses with clinical disease severity in acute dengue infection

Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections

Antibody-dependent DENV infection induces distinct transcriptomic responses in infected and bystander human macrophages

Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan

Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection

Conserved MHC Class I-presented Dengue Virus Epitopes Identified by Immunoproteomics Analysis Are Targets for Cross-Serotype Reactive T-cell Response.

Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections

Protective Role of NS1-Specific Antibodies in the Immune Response to Dengue Virus through Antibody-Dependent Cellular Cytotoxicity

Distinct Serum Exosomal Mirna Profiles Detected in Acute and Asymptomatic Dengue Infections: A Community-Based Study in Baiyun District, Guangzhou

The Innate Immune Response Following Multivalent Dengue Vaccination and Implications for Protection Against Dengue Challenge.

Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India—Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity

New insights into the immunopathology and control of dengue virus infection

Retrospective Seroepidemiology study of dengue virus infection in Taiwan

Dengue versus COVID-19: comparing the incidence of cardiovascular, neuropsychiatric and autoimmune complications

Immunomodulation in dengue: towards deciphering dengue severity markers

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells